Načítá se...
SAT-305 Hyperactive Behavioral Change during Combination Treatment of Aromatase Inhibitor and Recombinant Human Growth Hormone in Early Puberty Patient: A Case Report
Aromatase inhibitor (AI) is a drug that blocks the converstion of androgens to estrogens, originally approved by FDA as a treatment of breast cancer in postmenopausal women. In several studies, it has been proposed that AI can be used as a off-label treatment to improve the final adult height in sho...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551995/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-305 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|